SHANGHAI – Chia-Tai Tianqing Pharmaceutical Group Co. Ltd. (CTTQ), of Jiangsu, has taken steps to bring a biosimilar version of Pfizer Inc.'s Xyntha, a recombinant human coagulation factor VIII (rhFVIII), to the clinic and moves a step closer to providing a much-needed, affordable treatment for China's hemophilia A sufferers.